- Home
- TGE vs INBX Comparison
TGE vs INBX Comparison
Compare TGE & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGE
- INBX
- Stock Information
- Founded
- TGE 2023
- INBX 2010
- Country
- TGE France
- INBX United States
- Employees
- TGE N/A
- INBX N/A
- Industry
- TGE Newspapers/Magazines
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- TGE Consumer Discretionary
- INBX Health Care
- Exchange
- TGE Nasdaq
- INBX Nasdaq
- Market Cap
- TGE 290.8M
- INBX 345.8M
- IPO Year
- TGE N/A
- INBX 2020
- Fundamental
- Price
- TGE $3.59
- INBX $25.00
- Analyst Decision
- TGE
- INBX Hold
- Analyst Count
- TGE 0
- INBX 2
- Target Price
- TGE N/A
- INBX N/A
- AVG Volume (30 Days)
- TGE 53.0K
- INBX 107.2K
- Earning Date
- TGE 01-01-0001
- INBX 08-13-2025
- Dividend Yield
- TGE N/A
- INBX N/A
- EPS Growth
- TGE N/A
- INBX N/A
- EPS
- TGE 1.64
- INBX N/A
- Revenue
- TGE $77,014,000.00
- INBX $1,400,000.00
- Revenue This Year
- TGE N/A
- INBX N/A
- Revenue Next Year
- TGE N/A
- INBX N/A
- P/E Ratio
- TGE $2.26
- INBX N/A
- Revenue Growth
- TGE 81.03
- INBX N/A
- 52 Week Low
- TGE $2.99
- INBX $10.81
- 52 Week High
- TGE $37.02
- INBX $25.61
- Technical
- Relative Strength Index (RSI)
- TGE N/A
- INBX 65.23
- Support Level
- TGE N/A
- INBX $22.40
- Resistance Level
- TGE N/A
- INBX $24.48
- Average True Range (ATR)
- TGE 0.00
- INBX 1.39
- MACD
- TGE 0.00
- INBX 0.08
- Stochastic Oscillator
- TGE 0.00
- INBX 87.94
About TGE The Generation Essentials Group Class A Ordinary Shares
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.